Cargando…

Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo

Detalles Bibliográficos
Autores principales:	Li, Mengjiao, Ye, Zi-Wei, Tang, Kaiming, Guo, Liang, Bi, Wenwen, Zhang, Yuyuan, Tang, Yan-dong, Rong, Guoguang, Sawan, Mohamad, Yin, Xin, Sun, Ren, Yuan, Shuofeng, Dang, Bobo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007249/ https://www.ncbi.nlm.nih.gov/pubmed/35418217 http://dx.doi.org/10.1038/s41422-022-00656-4

Ejemplares similares

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
por: Yin, Wanchao, et al.
Publicado: (2022)

Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection
por: Guo, Liang, et al.
Publicado: (2020)

Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants
por: Bi, Wenwen, et al.
Publicado: (2022)

ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants
por: Ou, Jianxia, et al.
Publicado: (2022)

Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies
por: Shah, Masaud, et al.
Publicado: (2022)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

Trimeric receptor-binding domain of SARS-CoV-2 acts as a potent inhibitor of ACE2 receptor-mediated viral entry
por: Basavarajappa, Shrikanth C., et al.
Publicado: (2022)

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2
por: Zhang, Lianghui, et al.
Publicado: (2022)

Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
por: Han, Pengcheng, et al.
Publicado: (2022)

Deciphering the Impact of Mutations on the Binding Efficacy of SARS-CoV-2 Omicron and Delta Variants With Human ACE2 Receptor
por: Khan, Alamgir, et al.
Publicado: (2022)

Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex
por: Ching, Wai-Yim, et al.
Publicado: (2022)

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
por: Zhang, Zhaoyong, et al.
Publicado: (2021)

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
por: Zhang, Jing, et al.
Publicado: (2022)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer
por: Bharathi, Muruganantham, et al.
Publicado: (2022)

SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance
por: Zhang, Xiantao, et al.
Publicado: (2021)

SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses
por: Shah, Masaud, et al.
Publicado: (2022)

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
por: Zhang, Xinghai, et al.
Publicado: (2022)

Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers
por: Cheedarla, Narayanaiah, et al.
Publicado: (2023)

SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2
por: Wu, Leyun, et al.
Publicado: (2022)

A computational evaluation of structural stability of omicron and delta mutations of SARS-CoV-2 spike proteins and human ACE-2 interactions
por: Idowu, Kehinde A., et al.
Publicado: (2022)

Will New Variants Emerge after Delta and Omicron?
por: Yang, Zhen, et al.
Publicado: (2022)

Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike – ACE2 complexes reveal distinct changes between both variants
por: Socher, Eileen, et al.
Publicado: (2022)

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2022)

Scanning the RBD-ACE2 molecular interactions in Omicron variant
por: Rath, Soumya Lipsa, et al.
Publicado: (2022)

Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
por: Cacciottolo, Mafalda, et al.
Publicado: (2023)

A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
por: Wang, Yingdan, et al.
Publicado: (2022)

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
por: Zhang, Lianghui, et al.
Publicado: (2022)

Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants
por: Mäkelä, Anna R., et al.
Publicado: (2023)

SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig
por: Li, Yujun, et al.
Publicado: (2020)

SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody
por: Omotuyi, Olaposi, et al.
Publicado: (2022)

A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants
por: Chang, Ching-Wen, et al.
Publicado: (2022)

Omicron: Master of immune evasion maintains robust ACE2 binding
por: Hoffmann, Markus, et al.
Publicado: (2022)

Ceftazidime exhibits a broad inhibition to the infection of SARS-CoV-2 prototype and Omicron variant in vitro by blocking spike protein-ACE2 interaction
por: Zheng, Yun-zhe, et al.
Publicado: (2023)

Structural insights into the Omicron spike trimer: tackling the challenges of continuously evolving SARS-CoV-2 variants
por: Ou, Junxian, et al.
Publicado: (2022)

Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants
por: Chiuppesi, Flavia, et al.
Publicado: (2022)

SARS-CoV-2 spike protein S1 subunit induces potent neutralizing responses in mice and is effective against Delta and Omicron variants
por: Mamedov, Tarlan, et al.
Publicado: (2023)

Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM
por: Xu, Cong, et al.
Publicado: (2021)

Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
por: Lan, Jun, et al.
Publicado: (2022)

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant
por: He, Cai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_47em14lr9fov8quddbenc3e3b9